drugset / Trial / NCT00359632

Study to Evaluate Eye Function in Patients Taking Linezolid for Six Weeks or Greater

NCT00359632 ↗

Phase 3 Terminated 34 enrolled Pfizer
Non-randomizedParallel-groupOpen-label

Summary

To understand and characterize the effects of linezolid on the optic nerve by observing and following patients who have been treated with linezolid for six weeks or longer for the development of signs or symptoms of visual disturbance or eye disorders.

Timeline

Start
2008-11
Primary completion
2013-12
Completion
2013-12

Outcome

Outcome not reported

Stopped (Enrollment): “Study was stopped due to poor enrollment on 28 Feb 2012. Reason for termination was not due to safety concerns.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Linezolid Other / unclassified 600 mg —

Indications